Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 411 participants.

Also called NCT01375777

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 411 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01375777
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Canada, Denmark (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01375777. Randomized; quadruple masking; primary purpose treatment. Start 2011-07-06 (actual); primary completion 2012-03-02 (actual). Results posted on 2015-10-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels
Acronym
MENDEL
Condition
Hyperlipidemia
Intervention (Biological)
Evolocumab
Intervention (Drug)
Ezetimibe
Intervention (Other)
Placebo to Evolocumab
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01375777
Content hash
d1e2a05e8f222f23af1c592b66e2a9f129f61c662d733d16ade60f4d9a401bbe